Approved studies using CPRD Data

Access to CPRD data, including UK Primary Care Data, and linked data such as Hospital Episode Statistics, is subject to protocol approval via CPRD’s Research Data Governance (RDG) Process. Independent scientific and patient advice is provided by Expert Review Committees (ERCs) and the Central Advisory Committee (CAC). 

A summary of all approved protocols, including a lay and technical summary of the proposed research, is published three months after RDG approval. COVID-19 research protocols are being fast-tracked and all approved summaries are published within 72 hours to ensure transparency and to help avoid unnecessary duplication. 

Protocols below are listed in order of date of approval. Please click on the study title for more details. 

Peer-reviewed publications from research using CPRD data will be listed on our bibliography page

Approved studies using CPRD Data

Date of Approval Sort descending Title
06/07/2021 The effect of increasing physician workload on the choice of referrals to secondary care units and lab tests
08/07/2021 Trends in primary care prescribing of benzodiazepines, antipsychotics and beta-blockers for anxiety.
08/07/2021 Managing cardiovascular disease and risk in Covid-19 patients in primary care medicine
08/07/2021 Risk of Venous Thromboembolism After Knee, Hip or Shoulder Replacement: A Retrospective Cohort Study Using Linked Hospital and Primary Care Data
08/07/2021 An evaluation of the prevalence, epidemiology and burden of illness of bone and joint infections in the United Kingdom: a retrospective observational cohort study
09/07/2021 Managing cardiovascular disease and risk in Covid-19 patients in primary care medicine
11/07/2021 Evaluation of the real-world safety of angiotensin-converting enzyme inhibitors on the risk of lung cancer
13/07/2021 Alternative Confounding Control Approaches for the Prevalent New User Study Design: An Empirical Example Assessing the Effects of Antidiabetic Drug Exposure (sulfonylureas and GLP-1 analogs) on Hospitalization for Heart Failure
19/07/2021 Event Rates and Risk Factors for Atherosclerotic Cardiovascular Disease Events in High-Risk Primary Prevention and Atherosclerotic Cardiovascular Disease Populations in United Kingdom
22/07/2021 Identifying the clinical risks associated with COVID-19 in patients with congenital heart disease and associated co-morbidities
22/07/2021 A risk prediction model to predict incident heart failure (RiskHF): derivation and validation cohort study
29/07/2021 Determining treatment pathways, healthcare resource usage, and associated costs of patients with Myasthenia Gravis in England
29/07/2021 Event Rates and Risk factors for Cardiovascular Events in a United Kingdom Population with Hypertension
29/07/2021 Incretin-based drugs and the incidence of prostate cancer among patients with type 2 diabetes
02/08/2021 Epidemiology and healthcare resource utilisation associated with Duchenne muscular dystrophy
02/08/2021 Differences in morbidity and mortality in men and women with chronic obstructive pulmonary disease and peripheral arterial disease
05/08/2021 Concomitant use of biphasic insulin aspart and glucagon-like peptide-1 receptor agonist compared to modern basal insulin combined with glucagon-like peptide-1 receptor agonist: effect on glycaemic control in type 2 diabetes patients
09/08/2021 Respiratory infection related cardiovascular disease: a prognostic modelling and causal inference study
11/08/2021 Assessing the clinical and economic burden among patients with Clostridium Difficile Infection and recurrent Clostridium Difficile Infections: A real-world evidence study
16/08/2021 The Impact of COVID-19 on care for UK patients with chronic obstructive pulmonary disease (COPD) and patients with asthma